- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Correction to: PB006: A Natalizumab Biosimilar ; volume:44 ; number:9 ; day:3 ; month:9 ; year:2024 ; pages:729 ; date:9.2024
Clinical drug investigation ; 44, Heft 9 (3.9.2024), 729, 9.2024
- Urheber
-
Shirley, Matt
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40261-024-01388-6
- URN
-
urn:nbn:de:101:1-2412232110410.035272978996
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Shirley, Matt
- SpringerLink (Online service)
Ähnliche Objekte (12)
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: SB8: A Bevacizumab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: GP2015: An Etanercept Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Correction to: MYL-1402O: A Bevacizumab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Correction to: Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab
Correction to: Concurrent management of multiple sclerosis and natalizumab‑induced hepatitis with ofatumumab: a case report
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: SB8: A Bevacizumab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: GP2015: An Etanercept Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Correction to: MYL-1402O: A Bevacizumab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Correction to: Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab
Correction to: Concurrent management of multiple sclerosis and natalizumab‑induced hepatitis with ofatumumab: a case report
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: SB8: A Bevacizumab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: GP2015: An Etanercept Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Correction to: MYL-1402O: A Bevacizumab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Correction to: Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab